Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Lisaiceland is here to bring you a fully blockchained, democratized, healthcare AI...
Lisaiceland is here to bring you a fully blockc...
Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...
Cellectis is a clinical-stage biopharmaceutical...
Nymox Pharmaceutical Corporation specializes in the research and development of th...
Nymox Pharmaceutical Corporation specializes in...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...
Merck KGaA, Darmstadt, Germany, a leading scien...
InMode Ltd. (Nasdaq: INMD) is a leading global provider of innovative medical tech...
InMode Ltd. (Nasdaq: INMD) is a leading global ...
Founded in 1999, Dexcom, Inc. is the leader in transforming diabetes care and mana...
Founded in 1999, Dexcom, Inc. is the leader in ...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Join the National Investor Network and get the latest information with your interests in mind.